螺内酯不增加女性乳腺癌复发风险:回顾性分析
该回顾性分析基于Humana保险数据库,比较使用与未使用螺内酯的乳腺癌病史患者的复发率。结论认为螺内酯可考虑用于乳腺癌幸存者的脱发治疗。
要点
- 倾向匹配后螺内酯与乳腺癌复发无独立关联。
- 乳腺癌幸存者脱发可考虑使用螺内酯。
- 需注意回顾性研究的局限性。
核心结论
- 螺内酯与乳腺癌复发增加无独立关联,可考虑用于乳腺癌幸存者的脱发治疗。
研究设计与样本
- 回顾性分析使用Humana保险数据库,识别有乳腺癌病史的患者,按螺内酯处方分层并进行1:1倾向评分匹配。
临床怎么用
- 对于乳腺癌幸存者的脱发治疗,螺内酯可作为考虑选项。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Spironolactone is used off-label for androgenic alopecia because of its ability to arrest hair loss progression and long-term safety profile. However, little is known about the safety of spironolactone in breast cancer (BC) survivors. Because spironolactone has estrogenic effects, there is a theoretical risk for BC recurrence. Given that spironolactone is an important tool in the treatment of alopecia, we investigated whether spironolactone increased risk for BC recurrence. OBJECTIVE: To determine whether spironolactone is associated with increased BC recurrence. METHODS: A retrospective analysis was conducted using the Humana Insurance database. Patients with a history of BC were identified using International Classification of Diseases codes, stratified by spironolactone prescription, and also matched 1:1 using propensity score analysis. Patient characteristics and cancer recurrence rates between both cohorts were compared and analyzed. RESULTS: BC recurrence developed in 123 patients (16.5%) who were prescribed spironolactone compared with 3649 patients (12.8%) who developed BC recurrence without spironolactone prescribed (P = .004). After propensity matching, adjusted Cox regression analysis showed no association between spironolactone and increased BC recurrence (adjusted hazard ratio, 0.966; 95% confidence interval, 0.807-1.156; P = .953). LIMITATIONS: Retrospective study. CONCLUSION: Spironolactone was not independently associated with increased BC recurrence and may be considered for the treatment of alopecia in BC survivors.
引用
- Wei C, Bovonratwet P, Gu A, et al. Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis. J Am Acad Dermatol. 2020. PMID: 32446820. doi:10.1016/j.jaad.2020.05.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。